Yes. Compounded GHK-Cu troche requires a valid prescription from a licensed provider. All use is investigational and off-label. Informed consent is required before initiating therapy.

Transient blue discoloration of saliva during dissolution is normal and harmless. Mild oral irritation or sensitivity at the dissolution site may occur initially. Nausea and headache have been reported infrequently. No serious adverse effects have been documented at therapeutic doses in available clinical reports.

Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use tirzepatide. Consult your provider about all medications and conditions before starting.

Copper-chelating agents including D-penicillamine and trientine directly antagonize GHK-Cu and must not be used concurrently without specialist guidance. High-dose vitamin C or NAC may theoretically interfere with copper-mediated mechanisms at large supplemental doses. Patients on systemic immunosuppressants require provider evaluation given GHK-Cu's immune gene modulation activity.

Patients with active malignancy, Wilson's disease, or immunocompromising conditions require individualized provider evaluation and oncologist or specialist clearance before starting. This is an investigational compound. Provider review of your full medical history is required.